Literature DB >> 12910360

MELAS: clinical phenotype and morphological brain abnormalities.

M Sparaco1, A Simonati, T Cavallaro, L Bartolomei, M Grauso, F Piscioli, L Morelli, N Rizzuto.   

Abstract

We describe the clinical and neuropathological findings of three unrelated autopsy cases of MELAS harboring the A3243G transition in the mitochondrial DNA (mtDNA). Using immunohistochemical techniques, we studied the expression of several subunits of the respiratory chain in various brain regions from the same cases. In all three cases there was a reduced immunocytochemical staining for mtDNA-encoded subunits of the respiratory chain, confirming the presence of a defective mitochondrial protein synthesis in this disease. Mitochondrial abnormalities were mostly confined to multiple areas of different size and shape, in agreement with the focal character of the brain pathology in MELAS, and were most prominent in the cerebral cortex, providing a morphological contribution to the explanation of the cognitive regression of the patients. Immunoreactivity for mtDNA-encoded subunits was reduced in the walls of many pial and intracerebral arterioles of different brain regions but there was no clear correlation between territories of affected vessels and distribution of the histological and immunohistochemical lesions. Cerebral focal lesions in MELAS might have a metabolic nature and several pathogenetic mechanisms might be involved in the genesis of stroke-like episodes when there is a local increased ATP demand.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12910360     DOI: 10.1007/s00401-003-0716-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  9 in total

1.  Response regarding involvement of the cerebral veins in MELAS syndrome.

Authors:  Matthew T Whitehead; Michael Wien; Bonmyong Lee; Nancy Bass; Andrea Gropman
Journal:  Neuroradiology       Date:  2017-08-11       Impact factor: 2.804

2.  Cortical venous disease severity in MELAS syndrome correlates with brain lesion development.

Authors:  M T Whitehead; M Wien; B Lee; N Bass; A Gropman
Journal:  Neuroradiology       Date:  2017-06-30       Impact factor: 2.804

3.  The appearance of ADCs in the non-affected areas of the patients with MELAS.

Authors:  Zhenghua Liu; Xiwei Liu; Lihong Hui; Danhua Zhao; Xiaoying Wang; Sheng Xie; Jiangxi Xiao; Xuexiang Jiang
Journal:  Neuroradiology       Date:  2010-06-17       Impact factor: 2.804

4.  Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations.

Authors:  Andrey Y Abramov; Tora K Smulders-Srinivasan; Denise M Kirby; Rebeca Acin-Perez; José Antonio Enriquez; Robert N Lightowlers; Michael R Duchen; Douglass M Turnbull
Journal:  Brain       Date:  2010-02-15       Impact factor: 13.501

5.  Brain anomalies in maternally inherited diabetes and deafness syndrome.

Authors:  I Fromont; F Nicoli; R Valéro; O Felician; B Lebail; Y Lefur; J Mancini; V Paquis-Flucklinger; P J Cozzone; Bernard Vialettes
Journal:  J Neurol       Date:  2009-06-18       Impact factor: 4.849

6.  Neuroimaging characteristics in mitochondrial encephalopathies associated with the m.3243A>G MTTL1 mutation.

Authors:  Henriette J Tschampa; Horst Urbach; Susanne Greschus; Wolfram S Kunz; Cornelia Kornblum
Journal:  J Neurol       Date:  2012-11-30       Impact factor: 4.849

7.  Classificação das doenças neurometabólicas hereditárias baseada em aspectos radiológicos: ensaio iconográfico.

Authors:  André Felix Pedri; Marcelo Dos Santos Guedes; Cláudio Campi de Castro
Journal:  Radiol Bras       Date:  2022 Mar-Apr

Review 8.  Review: Central nervous system involvement in mitochondrial disease.

Authors:  N Z Lax; G S Gorman; D M Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2016-07-07       Impact factor: 8.090

9.  Investigating complex I deficiency in Purkinje cells and synapses in patients with mitochondrial disease.

Authors:  Alexia Chrysostomou; John P Grady; Alex Laude; Robert W Taylor; Doug M Turnbull; Nichola Z Lax
Journal:  Neuropathol Appl Neurobiol       Date:  2015-09-30       Impact factor: 8.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.